CDX therapy(Hemogenyx)

N/A

Report date: 2024/12/09 10:09:25

Base Information

Drug NameCDX therapy(Hemogenyx)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionAnti-CD3Tyrosine-protein kinase receptor FLT3 modulators
TargetsT cell surface glycoprotein CD3Tyrosine-protein kinase receptor FLT3
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesHemogenyx Pharmaceuticals PLC
China Registration ClassN/A

Develop Information

Active CompaniesHemogenyx Pharmaceuticals PLC
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A